Home Tags Novartis
The US just approved a $2.1 million treatment for a devastating disease. It’s the most expensive drug in the world.
The treatment, called Zolgensma, should last longer than a typical drug. It also has a much higher price tag.
Dispensed: Venture-backed insurance startup Bright Health’s 2018 results, a dispute between 2 drug giants, and the quest for a male birth contro...
Welcome to Dispensed, Business Insider's weekly newsletter giving you a dose of pharma, biotech, and healthcare news.
A top Novartis executive says the $225 billion drug giant is planning for a ‘doomsday scenario’ in cancer treatment
Pharma giant Novartis is developing drugs that could prevent cancer before patients get it. One big question: how will we pay for them?
A revolutionary drug that could treat a rare and devastating disease is prohibitively expensive. But one state has a plan to pay for its potential $5 ...
A one-time treatment for a devastating rare disease could be paid for with an installment plan in Massachusetts. That could set a roadmap for the US.
A huge lawsuit accuses nearly 20 big drug companies, a billionaire, and 2 brothers-in-law of cozying up to hike drug prices. Here’s the inside s...
Business Insider is the first to report on the unredacted suit, which alleges frequent, close communications among employees of rival companies about how to increase prices.
Tilray is soaring after announcing a deal with a unit of the Swiss drug giant Novartis to take its medical products global
Tilray rallied 10% Tuesday after saying it has partnered with a unit of Swiss drug giant Novartis to develop its medical cannabis products globally.
Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky
The Thursday announcement shows an end in sight for the 17-month saga that has stretched since Symjepi was first approved by U.S. regulators.
A big pharma CEO said he was ‘completely blindsided’ by his company’s deal with Trump’s former lawyer
Novartis CEO Vas Narasimhan said he was 'completely blindsided" when the drug company was thrown into the political spotlight over its contract with President Donald Trump's former lawyer.
Novartis is going after a $5 billion market with a new treatment for vision loss. That’s a big threat to Regeneron
Novartis' drug brolucizumab just showed that it wasn't any worse than Eylea, a drug from Regeneron, at treating an eye disease.
Endocyte, a US cancer-treatment provider, entered into a deal on Thursday to be acquired by Swiss drug maker Novartis. Endocyte shared exploded 50% to $23.48 apiece following the news.